Skip to main content
Enter the terms you wish to search for.
Select Search Option
This Site
All WCM Sites
Directory
Menu
Weill Cornell Medicine
Care
Discover
Teach
Rickman Lab
Explore this Website
Home
About Us
Toggle About Us menu options
Affiliations
Job Opportunities
Toggle Job Opportunities menu options
Postdoctoral Fellow in Cancer Research
Research Technician
Contact Us
Research
Toggle Research menu options
Projects
Toggle Projects menu options
N-MYC in NEPC
Lab Team
Toggle Lab Team menu options
Alumni
Fun Photos
Publications
News
Weill Cornell Medicine
Care
Discover
Teach
Home
About Us
Research
Lab Team
Publications
News
Home
Publications
Publications
Found 14 results
Author
Title
Type
Year
2023
Van Emmenis L
,
Ku S-Y
,
Gayvert K
,
Branch JR
,
Brady NJ
,
Basu S
,
Russell M
,
Cyrta J
,
Vosoughi A
,
Sailer V
et al.
. 2023.
The Identification of CELSR3 and Other Potential Cell Surface Targets in Neuroendocrine Prostate Cancer
.
Cancer Res Commun. 3(8):1447-1459.
2021
Brady NJ
,
Bagadion AM
,
Singh R
,
Conteduca V
,
Van Emmenis L
,
Arceci E
,
Pakula H
,
Carelli R
,
Khani F
,
Bakht M
et al.
. 2021.
Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer
.
Nat Commun. 12(1):3372.
2019
Berger A*
,
Brady NJ *
,
Bareja R
,
Robinson B
,
Conteduca V
,
Augello MA
,
Puca L
,
Ahmed A
,
Dardenne E
,
Lu X
et al.
. 2019.
N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer
.
J Clin Invest. 130:3924-3940.
2018
Rickman DS
,
Schulte JH
,
Eilers M
. 2018.
The Expanding World of N-MYC-Driven Tumors.
.
Cancer Discov. 8(2):150-163.
2017
Büchel G
,
Carstensen A
,
Mak K-Y
,
Roeschert I
,
Leen E
,
Sumara O
,
Hofstetter J
,
Herold S
,
Kalb J
,
Baluapuri A
et al.
. 2017.
Association with Aurora-A Controls N-MYC-Dependent Promoter Escape and Pause Release of RNA Polymerase II during the Cell Cycle.
.
Cell Rep. 21(12):3483-3497.
Rickman DS
,
Beltran H
,
Demichelis F
,
Rubin MA
. 2017.
Biology and evolution of poorly differentiated neuroendocrine tumors.
.
Nat Med. 23(6):1-10.
Wilkes DC
,
Sailer V
,
Xue H
,
Cheng H
,
Collins CC
,
Gleave M
,
Wang Y
,
Demichelis F
,
Beltran H
,
Rubin MA
et al.
. 2017.
A germline FANCA alteration that is associated with increased sensitivity to DNA damaging agents.
.
Cold Spring Harb Mol Case Stud. 3(5)
Dhingra P
,
Martinez-Fundichely A
,
Berger A
,
Huang FW
,
Forbes ANeil
,
Liu EMinwei
,
Liu D
,
Sboner A
,
Tamayo P
,
Rickman DS
et al.
. 2017.
Identification of novel prostate cancer drivers using RegNetDriver: a framework for integration of genetic and epigenetic alterations with tissue-specific regulatory network.
.
Genome Biol. 18(1):141.
2016
Gayvert KM
,
Dardenne E
,
Cheung C
,
Boland MRegina
,
Lorberbaum T
,
Wanjala J
,
Chen Y
,
Rubin MA
,
Tatonetti NP
,
Rickman DS
et al.
. 2016.
A Computational Drug Repositioning Approach for Targeting Oncogenic Transcription Factors.
.
Cell Rep. 15(11):2348-56.
Dardenne E
,
Beltran H
,
Benelli M
,
Gayvert K
,
Berger A
,
Puca L
,
Cyrta J
,
Sboner A
,
Noorzad Z
,
MacDonald T
et al.
. 2016.
N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer
.
Cancer Cell. 30(4):563-577.
2015
Beltran H
,
Eng K
,
Mosquera JMiguel
,
Sigaras A
,
Romanel A
,
Rennert H
,
Kossai M
,
Pauli C
,
Faltas B
,
Fontugne J
et al.
. 2015.
Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.
.
JAMA Oncol. 1(4):466-74.
2014
Galletti G
,
Matov A
,
Beltran H
,
Fontugne J
,
Mosquera JMiguel
,
Cheung C
,
MacDonald TY
,
Sung M
,
O'Toole S
,
Kench JG
et al.
. 2014.
ERG induces taxane resistance in castration-resistant prostate cancer.
.
Nat Commun. 5:5548.
2012
Rickman DS
,
T Soong D
,
Moss B
,
Mosquera JMiguel
,
Dlabal J
,
Terry S
,
MacDonald TY
,
Tripodi J
,
Bunting K
,
Najfeld V
et al.
. 2012.
Oncogene-mediated alterations in chromatin conformation.
.
Proc Natl Acad Sci U S A. 109(23):9083-8.
2011
Beltran H
,
Rickman DS
,
Park K
,
Chae SSuk
,
Sboner A
,
MacDonald TY
,
Wang Y
,
Sheikh KL
,
Terry S
,
Tagawa ST
et al.
. 2011.
Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets.
.
Cancer Discov. 1(6):487-95.